Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.55 |
| ▸ | IGF1R | P08069 | 5/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30760859 | 0.99 | NTRK1 (0.53) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL5805554 | 0.88 | MEN1 (0.43) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL28090395 | 0.80 | NTRK1 (0.55) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL28090360 | 0.79 | NTRK1 (0.51) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL30565799 | 0.78 | NTRK1 (0.56) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL17483820 | 0.77 | NTRK1 (0.55) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL30209639 | 0.76 | NTRK1 (0.48) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL18741408 | 0.75 | NTRK1 (0.56) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL28090357 | 0.75 | NTRK1 (0.52) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL30209637 | 0.75 | NTRK1 (0.52) | NTRK1NTRK2IGF1RFGFR1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186392-B2 | Combination therapy of an anti CD20 antibody with a BTK inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-07 | — | — | US | disclosed |
| EP-4359389-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117750946-A | Novel particulate compositions comprising sialic acid binding ligands | 希托迪格姆公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024037527-A1 | BTK DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-02-22 | — | — | WO | disclosed |
| CN-116568331-A | Pharmaceutical compositions of SIGLEC-binders | 希托迪格姆公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022271677-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115087488-A | Antibodies and fusion proteins binding to CCR8 and uses thereof | 震动疗法股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114555799-A | HBV vaccines and methods for treating HBV | 吉利德科学公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3975997-A1 | MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACE | Phosphorex, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114072130-A | Microparticles and nanoparticles having sulfate groups on the surface | 法斯瑞斯公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-106279172-A | Purinone compound as inhibitors of kinases | 药品循环有限责任公司 | 2017-01-04 | — | — | CN | disclosed |
| CN-104640861-B | Purinone compounds as kinase inhibitors | 药品循环公司 | 2016-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12186392-B2 | Combination therapy of an anti CD20 antibody with a BTK inhibitor | BTK, CD22, SYK | NTRK1 1941/4885NTRK2 3566/4885IGF1R 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.